Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. J Clin Oncol. 2013;31(15):1825-33. doi:10.1200/JCO.2013.48.7215
Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013;31(15):1803-5. doi:10.1200/JCO.2013.49.4799
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43-9. doi:10.1038/nature12222
Alföldi J, Lindblad-Toh K. Comparative genomics as a tool to understand evolution and disease. Genome Res. 2013;23(7):1063-8. doi:10.1101/gr.157503.113
Galagan JE, Minch K, Peterson M, et al. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature. 2013;499(7457):178-83. doi:10.1038/nature12337
Knoechel B, Lohr JG. Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes. J Autoimmun. 2013;45:15-23. doi:10.1016/j.jaut.2013.06.012
Roberts SA, Lawrence MS, Klimczak LJ, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013;45(9):970-6. doi:10.1038/ng.2702
Tamborero D, Gonzalez-Perez A, Perez-Llamas C, et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013;3:2650. doi:10.1038/srep02650
Ellis MJ, Gillette M, Carr SA, et al. Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discov. 2013;3(10):1108-12. doi:10.1158/2159-8290.CD-13-0219
McShane LM, Cavenagh MM, Lively TG, et al. Criteria for the use of omics-based predictors in clinical trials. Nature. 2013;502(7471):317-20. doi:10.1038/nature12564